Florian Huber

Title: Florian Huber - Innovator in Biotin-Specific Monoclonal Antibodies

Introduction

Florian Huber is a notable inventor based in Herrsching, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for various applications in diagnostics and research.

Latest Patents

Florian Huber holds a patent for a biotin-specific monoclonal antibody. This invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment, the monoclonal antibody does not bind to a biotin moiety on a biotinylated molecule, where the biotin moiety is attached via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. The patent also discloses a method for generating such an antibody. This monoclonal antibody is specifically useful in methods for measuring an analyte in a sample, utilizing a (strept)avidin/biotin pair to bind a biotinylated analyte-specific binding agent to a (strept)avidin coated solid phase.

Career Highlights

Florian Huber is currently employed at Roche Diagnostics Operations, Inc., where he continues to advance his research and development efforts. His work at Roche has positioned him as a key player in the field of diagnostics, contributing to innovative solutions that enhance the accuracy and efficiency of medical testing.

Collaborations

Florian has collaborated with notable colleagues, including Michael Gerg and Dieter Heindl. These collaborations have fostered a productive environment for innovation and have led to advancements in their shared field of expertise.

Conclusion

Florian Huber's contributions to the development of biotin-specific monoclonal antibodies exemplify the impact of innovative research in biotechnology. His work not only enhances diagnostic capabilities but also paves the way for future advancements in the field.